Jupiter Topco LLC Makes New Investment in TransMedics Group, Inc. $TMDX

Key Points

• Jupiter Topco purchased 15,263 TransMedics Group shares worth approximately $1.014 million in the second quarter. Institutional investors collectively own 99.67% of the company.
• Analyst sentiment is mixed: six analysts rate TMDX a Buy, six rate it Hold, and one rates it Sell. The consensus rating is Hold, with an average price target of $124.18, although several firms recently lowered their targets.
• TransMedics reported quarterly revenue of $189.95 million, up 20.7% year over year and above estimates, but earnings per share of $0.44 missed the $0.50 consensus. The stock opened at $89.98 and has traded between $60.10 and $156.00 over the past year.

Jupiter Topco LLC purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 15,263 shares of the company's stock, valued at approximately $1,014,000.

Several other institutional investors and hedge funds have also modified their holdings of TMDX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of TransMedics Group by 11.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company's stock valued at $119,997,000 after acquiring an additional 113,817 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in TransMedics Group by 50.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company's stock worth $117,506,000 after purchasing an additional 322,353 shares during the period. Geode Capital Management LLC grew its holdings in TransMedics Group by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 816,474 shares of the company's stock valued at $99,339,000 after purchasing an additional 2,903 shares during the last quarter. Two Sigma Investments LP grew its holdings in TransMedics Group by 54.2% during the third quarter. Two Sigma Investments LP now owns 635,394 shares of the company's stock valued at $71,291,000 after purchasing an additional 223,409 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of TransMedics Group by 43.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company's stock valued at $69,338,000 after purchasing an additional 171,810 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on TMDX. TD Cowen reissued a "buy" rating and set a $120.00 target price on shares of TransMedics Group in a research report on Wednesday, July 1st. Zacks Research cut TransMedics Group from a "hold" rating to a "strong sell" rating in a research report on Monday, July 6th. Piper Sandler restated an "overweight" rating and set a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Needham & Company LLC lowered their target price on TransMedics Group from $142.00 to $106.00 and set a "buy" rating on the stock in a report on Monday, August 3rd. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $124.00 price target on shares of TransMedics Group in a research report on Tuesday, June 30th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $124.18.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $89.98 on Friday. The firm has a market capitalization of $3.11 billion, a PE ratio of 23.13 and a beta of 1.90. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. TransMedics Group, Inc. has a 12-month low of $60.10 and a 12-month high of $156.00. The firm has a 50-day moving average price of $80.14 and a 200 day moving average price of $92.21.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The company had revenue of $189.95 million for the quarter, compared to analyst estimates of $184.00 million. During the same period in the previous year, the firm posted $0.92 earnings per share. The firm's revenue for the quarter was up 20.7% compared to the same quarter last year. Research analysts anticipate that TransMedics Group, Inc. will post 1.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the company's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the sale, the director directly owned 16,642 shares in the company, valued at $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by corporate insiders.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.